The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

aerovance.com

Founded Year

2004

Stage

Dead | Dead

Total Raised

$150.5M

About Aerovance

Aerovance is a biopharmaceutical company focused on the development and commercialization of clinical-stage products for respiratory and allergic diseases. Aerovance's lead programs are in development for the treatment of uncontrolled asthma and uncontrolled eczema. The company is also developing programs for cystic fibrosis and chronic obstructive pulmonary disease. Aerovance was spun off from Bayer Healthcare's biotechnology unit in August 2004.

Aerovance Headquarter Location

2929 Seventh Street Suite 120

Berkeley, California, 94710,

United States

510-549-5538

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Aerovance Patents

Aerovance has filed 3 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/11/2007

5/24/2011

Immunology, Interleukins, Transcription factors, Immune system, Monoclonal antibodies

Grant

Application Date

1/11/2007

Grant Date

5/24/2011

Title

Related Topics

Immunology, Interleukins, Transcription factors, Immune system, Monoclonal antibodies

Status

Grant

You May Also Like

B
Bikam Pharmaceuticals

BIKAM Pharmaceuticals, Inc. is an early stage biopharmaceutical company focusing upon the discovery and development of small molecule therapeutics for the treatment of ophthalmic diseases and disorders, including retinitis pigmentosa. Worldwide, there are approximately 1.5 million people which suffer from retinitis pigmentosa (RP), a hereditary disease which leads to blindness. As its initial priority, the company is pursuing the discovery of compounds based on a novel mechanism of action identified by the company's founder, Dr. Shalesh Kaushal. BIKAM has an experienced management team with a strong track record in pharmaceutical drug discovery dedicated to expanding these findings and others from the Kaushal lab to create potential therapeutics to prevent blindness.

B
BioMarck Pharmaceuticals

BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.

T
Topigen Pharmaceuticals

Topigen is a biopharmaceutical company developing several new classes of drugs for respiratory disorders based upon its platform technology using DNARNA chemistry. These drugs are focused on inhibiting multiple inflammatory pathways at the cellular site of inflammation using a single drug product. Per the company, this approach has shown promising preclinical results in inhibiting the underlying inflammation associated with many pulmonary conditions such as asthma COPD and allergic rhinitis AR.

S
Selectx Pharmaceuticals

SelectX Pharmaceuticals is a biopharmaceutical company that focuses on the discovery and development of small molecule antimicrobials and other therapeutics for unmet medical needs through the application of its Genetic Chemistry platform.

A
Affectis Pharmaceuticals

Affectis Pharmaceuticals, fka neuronova, is a biopharmaceutical company developing drugs for the treatment of psychiatric and inflammatory disorders.

ARC Pharmaceuticals Logo
ARC Pharmaceuticals

ARC Pharmaceuticals Inc. is a privately owned biotechnology company developing medical products for the treatment of proliferative diseases. The Company holds exclusive intellectual property related to the treatment of surgical adhesions, rheumatoid arthritis, osteoarthritis and psoriasis. ARC's initial focus is on the prevention of surgical adhesion disease, a major complication in a high proportion of common surgical procedures causing pain and dysfunction in millions of patients worldwide.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.